Want to see MIR full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.1Last Year’s EPS
0.11Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum driven by large order growth, a materially expanded backlog, robust contributions from the Paragon and CertRec acquisitions, and sustained improvement in core end markets (notably nuclear power, SMRs, and Medical RTQA). Financial performance showed healthy revenue (+28%) and adjusted EBITDA (+16%) growth, with management maintaining full-year guidance and forecasting stronger sequential orders. Near-term headwinds were primarily margin dilution from recent M&A, seasonal and timing-related cash flow weakness, and some regional/new-build softness in Asia, but these were framed as manageable and addressable through integration synergies, operational improvements, and expected cash conversion later in the year. Overall, positive operational and market developments materially outweigh the transitory challenges described.Company Guidance
Nuclear Power and SMR Momentum
Nuclear & Safety revenue was $186M, up 39% year-over-year. Nuclear power orders (excluding M&A) grew 15% in Q1 and nuclear power revenue (excluding M&A) increased 4% despite a tough comp; SMR orders booked ~ $15M in Q1 and a $35M SMR award in April. SMR-related revenue represents ~2% of total revenue and is expected to exceed 3% by year-end.
Medical Segment Recovery and Key Wins
Medical revenue was $72M, up 5% year-over-year with ~4% organic growth. RTQA posted double-digit organic growth driven by software strength and a large radiation-tolerant camera order tied to the Varian partnership; nuclear medicine remains on track for double-digit organic revenue growth in 2026.
Capital Allocation and Cash Generation
Company used ~$16M of its $100M share repurchase program in Q1 to buy ~700k shares. Adjusted free cash flow was $11M in Q1 (noted as seasonally light); management expects stronger cash generation in later quarters and remains on track for full-year adjusted free cash flow guidance.
Guidance and Near-Term Outlook
2026 guidance remained unchanged (small EPS adjustment for a one-time CEO retention grant). Management expects Q2 orders to be 15%–20% higher sequentially, consolidated Q2 organic revenue growth in the low single digits, and relatively flat consolidated adjusted EBITDA margins versus Q2 2025 (with legacy Nuclear & Safety margins expanding if Paragon excluded).
Strong Order Growth
Total orders increased 42% year-over-year to $288M including Paragon and CertRec; orders excluding M&A grew 19% to $241M. Company won $50M of large opportunity orders in Q1 and an additional $35M SMR-related order in April.
Backlog Expansion
Backlog reached $1.1B, up 38% including M&A and 19% excluding M&A, representing a step change after back-to-back strong Q4 and Q1 order quarters and providing multi-quarter revenue visibility.
Revenue and Organic Growth
Consolidated Q1 revenue was $258M, up 28% year-over-year. Organic revenue growth was 3%, in line with guidance and expectations.
Adjusted EBITDA and EPS Improvement
Q1 adjusted EBITDA was $54M, an increase of 16% versus prior year. Adjusted EPS was $0.10 for the quarter (would have been $0.08 under prior methodology).
Paragon and CertRec Acquisition Momentum
Paragon contributed meaningfully to orders and revenue (Paragon first-quarter revenue grew ~45%). M&A added roughly $43M (Paragon) and $47M combined (Paragon + CertRec) to orders in the quarter. Early commercial synergies produced incremental order wins and cross-sell opportunities.
MIR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MIR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 28, 2026 | $18.68 | $18.66 | -0.11% |
Feb 10, 2026 | $23.44 | $21.05 | -10.20% |
Oct 28, 2025 | $25.19 | $29.75 | +18.10% |
Jul 31, 2025 | $22.35 | $19.86 | -11.14% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Mirion Technologies, Inc. (MIR) report earnings?
Mirion Technologies, Inc. (MIR) is schdueled to report earning on Jul 30, 2026, Before Open (Confirmed).
What is Mirion Technologies, Inc. (MIR) earnings time?
Mirion Technologies, Inc. (MIR) earnings time is at Jul 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MIR EPS forecast?
MIR EPS forecast for the fiscal quarter 2026 (Q2) is 0.1.